EpiPen Class Action Lawsuit Settlement, Payments, Eligibility & What to Do Now

Millions of Americans who purchased EpiPens between August 24, 2011, and November 1, 2020 were covered by a combined $609 million in class action settlements against Pfizer and Mylan. For businesses that purchased EpiPens directly from manufacturers, a separate $73.5 million Mylan settlement also applies. The consumer claim filing windows are now closed, but if you filed a claim, this guide explains your payment status and next steps. Visit EpiPenClassAction.com for the most current updates.

Key Dates at a Glance

Lawsuit Overview

Plaintiffs in the class action alleged that Mylan may have worked with Pfizer to artificially raise the price of life-saving EpiPen products, claiming the companies knowingly violated antitrust and racketeering laws through their scheme — with the goal of monopolizing the market for epinephrine autoinjector devices. Mylan denied that it violated any laws, but agreed to settle to avoid the costs and risks of continued litigation.

The price impact on consumers was severe. Consumers filed their EpiPen class action lawsuit in 2017 claiming Pfizer and Mylan plotted to maintain EpiPen’s monopoly by issuing large rebates to insurers and Medicaid plans that refused to cover competing medications — and the class action was filed after the price of EpiPens rose from $100 to $600 in under 10 years.

Settlement Amount Breakdown

There are two separate settlement tracks — one for everyday consumers and insurers (“indirect purchasers”), and one for businesses that bought directly from the manufacturer (“direct purchasers”). Here is how each breaks down.

Consumer (Indirect Purchaser) Settlement

The $264 million Mylan settlement brought the total recovery to EpiPen class members to $609 million, combining the earlier $345 million Pfizer settlement.

Attorney fees and administration costs are deducted from each settlement fund before distribution. Attorney fees and other expenses are paid from the settlement fund. The exact dollar amounts awarded for fees and administration in each fund were determined by the court and are available in the final judgment documents at EpiPenClassAction.com under “Court Documents.”

Direct Purchaser Settlement

A $73,500,000 settlement was reached with Mylan in the case KPH Healthcare Services, Inc. v. Mylan N.V., Case No. 2:20-cv-02065-DDC-TJJ, pending in the United States District Court for the District of Kansas. Combined with a separate $50 million Pfizer direct purchaser settlement, the total direct purchaser recovery is $123.5 million.

Who Was Eligible

Consumer Class (Indirect Purchasers)

You qualified as a class member if you are a person or entity in the United States who paid or provided reimbursement for some or all of the purchase price of branded or authorized generic EpiPens for the purpose of consumption, and not resale, by yourself, your family members, insureds, plan participants, employees, or beneficiaries, at any time between August 24, 2011, and November 1, 2020, and did not exclude yourself from the class during the initial notice period.

Covered products included:

• EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors
• EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors
• Epinephrine Injection, USP Auto-Injectors (the authorized generic for EpiPen®)

Direct Purchaser Class

You are part of the Direct Purchaser Class if you are a person or entity in the United States or its territories, possessions, and the Commonwealth of Puerto Rico that purchased EpiPen or generic EpiPen directly from Mylan or Teva, for resale, at any time during the period from March 13, 2014, until February 6, 2025.

Direct purchasers are generally entities or individuals who acquired the product straight from the pharmaceutical manufacturer — this group can include drug wholesalers, organizations that purchase medications in bulk, and institutional buyers such as hospitals, clinics, or other healthcare facilities that procure drugs directly.

Who Is Not Eligible

• Anyone who purchased EpiPens outside the covered time periods (before August 24, 2011, or after November 1, 2020 for consumers; before March 13, 2014, or after February 6, 2025 for direct purchasers)
• Anyone who excluded themselves from the class during the opt-out period
• Direct purchasers filing as consumers: If you bought EpiPen directly from the manufacturer for resale, the consumer settlement does not cover you — the direct purchaser settlement applies instead
• Anyone filing a duplicate claim: If you already submitted a Proof of Claim form during the Pfizer settlement in 2021, you did not need to submit a second claim for the Mylan settlement — your earlier form was used for both.
• Fraudulent filers: Filing a false claim is done under penalty of perjury and harms other eligible class members

Payment Calculation: How the Money Was Divided

Step 1 — The Two-Pool System

The net settlement fund — the amount left over after attorney fees, costs, and noticing fees — was allocated into two pools: one for individual consumer class members and one for third-party payor (“TPP”) class members. This allocation was 20% for the individual consumer pool and 80% for the TPP class member pool.

Step 2 — Your Share Within the Pool

Within each pool, a class member’s actual recovery is a proportion of that pool determined by that class member’s allowed claim compared to the total allowed claims of all class members in the same pool who submitted acceptable and timely proofs of claim.

In plain terms: the more you spent on EpiPens during the covered period, the larger your proportional share of the consumer pool.

For direct purchasers: the court-approved plan of allocation proposes distributing remaining settlement funds after costs and expenses based upon the number and cost of purchases made during the class period.

Step 3 — Real Payment Examples (Consumer Settlement)

These are reported actual payment ranges, not guarantees. Final amounts depended on the total number of valid claims submitted.

This class action settlement paid out up to $3,780.72 as of June 9, 2023. EpiPen class action claimants reported receiving emails that included payments upwards of $1,500 as of June 28, 2023.

Step 4 — What Remains Unknown

Per the settlement structure, the final per-claimant amount depended entirely on how many valid claims were approved. Payment amounts were not disclosed to claimants until they received a second email from the administrator containing a live link to redeem digital payment.

How Payments Were Delivered (Consumer Settlement)

Consumers with a valid claim received an initial email from [email protected] with instructions on how to redeem payment through a digital payment process. Payments were made via a choice of virtual prepaid MasterCard, PayPal, direct deposit, or Venmo.

If you filed a claim and have NOT received payment: Check your spam folder for emails from [email protected]. Contact the settlement administrator directly:

• Email: [email protected]
• Phone: 1-877-221-7632
• Mail: EpiPen Settlement c/o A.B. Data, Ltd., P.O. Box 173113, Milwaukee, WI 53217

If you previously filed a claim but have not received a check, visit EpiPenClassAction.com and use your Claim ID to verify if your form was flagged for “deficiency” due to missing paperwork.

Direct Purchaser Claims: Current Status (2026)

The May 29, 2025 claim deadline for the Mylan direct purchaser settlement has now passed. The court must grant final approval to the settlement before payments are issued, and once final approval is granted, payments will be distributed to valid claimants.

If you represent a business that purchased EpiPens directly, ensure your tax documentation is up to date with the administrator, A.B. Data, Ltd., at 1-877-221-7632.

Contact for direct purchaser inquiries:

• Website: EpiPenDPPSettlement.com
• Email: [email protected]
• Phone: 866-778-6568
• Mail: EpiPen Direct Purchaser-Mylan Settlement c/o A.B. Data, Ltd., P.O. Box 173113, Milwaukee, WI 53217

What You Must Know

Taxes: Settlement payments may or may not be taxable depending on your specific situation. This article does not provide tax advice. Consult a tax professional if you have questions about reporting your payment.

Opt-out consequences: Class members who opted out of the settlement gave up their right to receive a payment but retained the right to sue Mylan or Pfizer independently.

Common filing mistakes: Submitting a duplicate claim, providing an incorrect email address, or failing to respond to deficiency notices from the administrator are the most common reasons valid claimants do not receive payment. Do not file a claim if you do not qualify — claims are submitted under penalty of perjury.

Uncashed payments: If you were a claimant and have not received a settlement payment, check your email’s spam folder for any email about an uncashed check and respond immediately.

Leftover funds: Any remaining balance in the net settlement fund that is no longer economically feasible to distribute to class members will be donated to the Allergy and Asthma Foundation of America, Allergy and Asthma Network, Allison Rose Foundation, and Food Allergy & Anaphylaxis Connection Team, if approved by the Court.

Frequently Asked Questions

1. Is the EpiPen class action settlement still open? No. The consumer claim deadline closed July 25, 2022. The direct purchaser deadline closed May 29, 2025. New claims are not being accepted.

2. How much did the EpiPen settlement pay out? The Pfizer consumer settlement paid out up to $3,780.72. Mylan settlement claimants reported payments upwards of $1,500 as of June 2023. Amounts varied based on each claimant’s purchase history.

3. I filed a claim but never got paid. What should I do? Contact A.B. Data, Ltd. at 1-877-221-7632 or [email protected]. Check your spam folder for emails from [email protected]. Use your Claim ID on EpiPenClassAction.com to check for deficiency notices.

4. What was the total EpiPen settlement amount? The combined total recovery for consumer class members reached $609 million, combining the $345 million Pfizer settlement and the $264 million Mylan settlement.

5. Who qualified for the EpiPen settlement? Any person or entity in the United States who paid or provided reimbursement for branded or authorized generic EpiPens for consumption purposes between August 24, 2011, and November 1, 2020.

6. Did I need proof of purchase to file an EpiPen claim? No documentation was required at the time of filing. However, the settlement administrator may have requested additional proof supporting the claim.

7. What was the EpiPen lawsuit about? The litigation alleged that Mylan (Viatris) and Pfizer engaged in a “pay-for-delay” scheme, conspiring to keep lower-cost generic versions of the life-saving epinephrine injector off the market — allowing the price of an EpiPen 2-Pak to skyrocket from roughly $100 to over $600 in less than a decade.

8. What is the direct purchaser EpiPen settlement? A separate $123.5 million settlement covers direct purchasers — entities like pharmacies, wholesalers, and hospitals that bought EpiPen directly from the manufacturer, not through retail channels.

9. How was the EpiPen settlement money split? Under the terms of the Mylan settlement, 20% of the net settlement fund went to individual consumers who purchased EpiPens, and 80% went to third-party payors such as insurance companies that reimbursed consumers.

10. Can I still get money from the EpiPen settlement in 2026? While the window for individual consumers largely closed in 2022, direct purchasers within the processing window for the $73.5 million Mylan fund may still be within a payment processing period. Contact the administrator at 866-778-6568 or visit EpiPenDPPSettlement.com for current status.

Last Updated: February 17, 2026. This article reflects verified information available as of this date. Contact the settlement administrator or visit the official settlement websites for the most current information.

Disclaimer: This article is for informational purposes only and does not constitute legal or tax advice. Settlement terms, eligibility, and payment amounts are subject to court approval and may change. For official information, always refer to the settlement administrator or the official settlement website.

About the Author

Sarah Klein, JD, is a licensed attorney and legal content strategist with over 12 years of experience across civil, criminal, family, and regulatory law. At All About Lawyer, she covers a wide range of legal topics — from high-profile lawsuits and courtroom stories to state traffic laws and everyday legal questions — all with a focus on accuracy, clarity, and public understanding.
Her writing blends real legal insight with plain-English explanations, helping readers stay informed and legally aware.
Read more about Sarah